Aclaris Therapeutics Presents Phase 2a Data for ATI-2138 in Atopic Dermatitis at AAD 2026
Event summary
- Aclaris Therapeutics will present Phase 2a trial results for ATI-2138, an oral covalent inhibitor of ITK and JAK3, at the 2026 AAD Annual Meeting.
- The open-label trial evaluated ATI-2138 in moderate-to-severe atopic dermatitis patients.
- The ePoster includes previously unreported data from the Phase 2a trial.
- The trial was conducted by Aclaris Therapeutics, with collaboration from the Icahn School of Medicine at Mount Sinai.
The big picture
Aclaris Therapeutics' presentation of Phase 2a data for ATI-2138 at the AAD 2026 Annual Meeting marks a critical milestone in the development of novel treatments for atopic dermatitis. The focus on oral covalent inhibitors of ITK and JAK3 aligns with the broader industry trend toward targeted therapies for immuno-inflammatory diseases. The success of ATI-2138 could potentially disrupt the current treatment landscape, which is dominated by topical and systemic therapies with varying efficacy and safety profiles.
What we're watching
- Clinical Efficacy
- How the Phase 2a data for ATI-2138 will position it against existing treatments for atopic dermatitis.
- Regulatory Pathway
- The pace at which Aclaris Therapeutics can advance ATI-2138 into later-stage trials based on these results.
- Market Differentiation
- Whether ATI-2138's dual inhibition of ITK and JAK3 will offer a competitive advantage in the immuno-inflammatory disease space.